About adlai nortye ltd - ANL
Adlai Nortye Ltd. is a clinical-stage biopharmaceutical company, which engages in the provision of development of cancer therapies for patients with stages of tumors. It offers AN0025, a clinical stage, potential EP4 antagonist designed to modulate tumor microenvironment. The company was founded on May 9, 2018, and is headquartered in Hangzhou, China.
ANL At a Glance
Adlai Nortye Ltd.
Building 6 & 8
Hangzhou, Zhejiang 311100
| Phone | 86-571-289-8385 | Revenue | 0.00 | |
| Industry | Miscellaneous Commercial Services | Net Income | -51,895,016.36 | |
| Sector | Commercial Services | Employees | 123 | |
| Fiscal Year-end | 12 / 2025 | |||
| View SEC Filings |
ANL Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 3.888 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -0.982 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 0.523 |
ANL Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -421,910.702 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
ANL Liquidity
| Current Ratio | 1.412 |
| Quick Ratio | 1.412 |
| Cash Ratio | 1.343 |
ANL Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -51.519 |
| Return on Equity | -98.953 |
| Return on Total Capital | -98.452 |
| Return on Invested Capital | -98.117 |
ANL Capital Structure
| Total Debt to Total Equity | 106.831 |
| Total Debt to Total Capital | 51.651 |
| Total Debt to Total Assets | 38.201 |
| Long-Term Debt to Equity | 1.668 |
| Long-Term Debt to Total Capital | 0.806 |